title: Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses.
abstract: BACKGROUND
  Systemic non-Langerhans cell histiocytoses are disorders characterized by the accumulation of histiocytes that do not meet the criteria for Langerhans cells in various organs. So far, no causative treatment is known.
  
  
  METHODS
  Herein, we report the case of a 41-year-old man with Rosai-Dorfman disease, a form of systemic non-Langerhans cell histiocytoses, with histiocytic infiltrations in the skin, bone marrow, liver, and spleen. Histiocytes were positive for the imatinib target proteins platelet-derived growth factor receptor beta and KIT. The disease completely responded to treatment with 400 to 600 mg daily of imatinib for more than 7 months.
  
  
  CONCLUSIONS
  This case shows that imatinib is a powerful treatment option for patients with non-Langerhans cell histiocytoses.
authors.affiliation: Department of Dermatology, Venereology, and Allergology, Central Laboratory, University Medical Center Mannheim, Ruprecht-Karl-University of Heidelberg, Germany. jutikal@mgh.harvard.edu
authors.forename: Jochen
authors.initials: J
authors.lastname: Utikal
authors.forename: Selma
authors.initials: S
authors.lastname: Ugurel
authors.forename: Hjalmar
authors.initials: H
authors.lastname: Kurzen
authors.forename: Philipp
authors.initials: P
authors.lastname: Erben
authors.forename: Andreas
authors.initials: A
authors.lastname: Reiter
authors.forename: Andreas
authors.initials: A
authors.lastname: Hochhaus
authors.forename: Thomas
authors.initials: T
authors.lastname: Nebe
authors.forename: Ralf
authors.initials: R
authors.lastname: Hildenbrand
authors.forename: Uwe
authors.initials: U
authors.lastname: Haberkorn
authors.forename: Sergij
authors.initials: S
authors.lastname: Goerdt
authors.forename: Dirk
authors.initials: D
authors.lastname: Schadendorf
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001549:Benzamides; D003937:Diagnosis, Differential; D015616:Histiocytosis, Non-Langerhans-Cell / Q000175:diagnosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D008279:Magnetic Resonance Imaging; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use*; D012720:Severity of Illness Index
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases